chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Fever 100.6 24 hours after vaccination ,  Headache chills and body aches,  muscle  ache .
20SEP97 fever of 104 @ 3AM but mom states felt hot by the time got home on 19SEP97 p/vax;given APAP to lower fever;
Moderna COVID-19 Vaccine EUA  Patient received Moderna second dose on 3/29/21 at 8:30 am and experienced weakness in legs later that day around 3:00 pm.  Presented to emergency department on 3/30/21 with complaints of generalized body aches and numbness to both legs and lower arms, feeling like legs had fallen asleep.  Initial examination in ED revealed sensory deficit with final diagnosis of myelitis, acute transverse and Guillain-Barre Syndrome after administration of vaccine. On 4/1/21, continuing to experience numbness with some ascending pattern, slight decrease in reflexes.
Information has been received from a physician's assistant concerning a 23 year old female patient with hallucinations induced by steroids who on 22-APR-2009 was vaccinated IM with the first dose of GARDASIL and on 22-JUN-2009 received IM the second dose of GARDASIL (lot #662518/0087Y). There was no concomitant medication. On 28-JUN-2009, the patient developed rash on lower extremities and chest, wheezing, tachycardia and intermittent fever. The patient sought unspecified medical attention. The patient's final outcome was not reported. Additional information has been requested.
Patient reported vaccinated arm felt "asleep" during night following vaccination. (Weakness and numbness.) Sx resolved by following morning but sensation of "fatigue" in affected arm persisted for two days.
pt recv vax 24MAY95 & 29APR97 pt devel a severe case of chickenpox;It was reported that pt had pox on every eyelid & mucous membrane;
Case number PHEH2014US021163 is an initial spontaneous report received from a pharmacist on 17 Oct 2014. This report refers to a patient whose identifiers were not reported. The patient's medical history and concomitant medications were not reported. It was reported that on an unknown date this patient received only the Men CYW-135 liquid conjugate component of MENVEO (batch number: not reported) intramuscularly and did not receive Men A powder lyophilized conjugate component. No adverse events were reported following the medication error.
ACUTE RESPIRATORY FAILURE ACUTE HYPOXEMIC RESPIRATORY FAILURE HYPOXIA 11/12/2022  &  11/20/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Multiple myalgia/arthralgia to back, joint, shoulders, lower back pain, visual problems, dizziness, sleep disorder, knee injury, respiratory problems, headaches, fatigue, and memory loss since June 04 AVA and deployment 2004.
Received DTaP in the Rt. Deltoid on Wed. May 19, 2004. Childs mother called today to report swelling redness & warmth to the Rt. Deltoid area. Also received polio sub Q in this arm, but this was administered below the deltoid and laterally. RN recommended to watch for fever, systemic symptoms and recommended a cool compress prn.
got a flu shot around that time and was wondering if that caused him to feel sick; since last fill caught a cold; cough; Initial information received on 10-Nov-2022 regarding an unsolicited valid  non-serious case received from a consumer/non-hcp.  This case involves Adult male patient who since last fill caught a cold, cough  and got a flu shot around that time and was wondering if that caused him to feel sick while receiving vaccine influenza vaccine and while treated with dupilumab [Dupixent].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 14-Oct-2022, the patient started taking dupilumab at a dose of 600 mg TOTAL once via subcutaneous route (strength: 150 mg/mL, lot - Unknown) for Atopic dermatitis. On an unknown date, dupilumab dosage was changed to 300 mg QOW for Atopic dermatitis.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (formulation, strength, dose and lot number not reported) via unknown route in unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious events of got a flu shot around that time and was wondering if that caused him to feel sick (malaise), since last fill caught a cold (nasopharyngitis) and cough (unknown latency) following the first dose intake of dupilumab and (unknown latency) following the administration of influenza vaccine.  It was reported, since last fill, "caught a cold." pt not sure if was a side effect. he believed he started feeling sick about 3 weeks ago, but last dose of dupixent was about a week after that, so doesn't think it was from the shot. he also says he got a flu shot around that time and was wondering if that caused him to feel sick he slates that only the cough remains, but it is bothering him he will speak to and about it and see if he can get something for the cough.   Action taken with DUPILUMAB (DUPIXENT) was unknown. Action taken with INFLUENZA VACCINE (INFLUENZA VACCINE) was not applicable.  It was not reported if the patient received a corrective treatment for the events (since last fill caught a cold, got a flu shot around that time and was wondering if that caused him to feel sick, cough).  At time of reporting, the outcome was Unknown for all the events.
BAD SKIN REACTION; PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE; OFF LABEL USE; This spontaneous report received from a consumer via a company representative concerned a 14 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 16-OCT-2021 for prophylactic vaccination. The batch number was not reported. The company was unable to perform follow-up to request batch/lot number. No concomitant medications were reported. On 16-OCT-2021, the patient experienced product administered to patient of inappropriate age. On 16-OCT-2021, the patient experienced off label use. On an unspecified date, the patient experienced bad skin reaction. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from bad skin reaction, and the outcome of product administered to patient of inappropriate age and off label use was not reported. This report was non-serious.
This case was reported by a pharmacist via call center representative and described the occurrence of rash in a 67-year-old patient who received SHINGRIX for prophylaxis. On 20th August 2018, the patient received the 1st dose of SHINGRIX .5 ml. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced rash and pruritus. On an unknown date, the outcome of the rash and pruritus were recovered/resolved. It was unknown if the reporter considered the rash and pruritus to be related to SHINGRIX. Additional details were provided as follows: The reporter reported that, the patient developed a rash and itching that lasted for 10 days after receiving the SHINGRIX. The reporter did not have vaccine information and did not feel comfortable providing all patient details.
EXPIRED VACCINE ADMINISTERED; This spontaneous report received from a pharmacist concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 201A21A, and expiry: 21-SEP-2021) dose was not reported, administered on 23-SEP-2021 for prophylactic vaccination. No concomitant medications were reported. On 23-SEP-2021, the patient experienced expired vaccine administered. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of expired vaccine administered was not reported. This report was non-serious. This case, from the same reporter is linked to 20210950001.
This spontaneous report was received from the patient's mother referring to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. A nurse from the doctor's office indicated to the patient's mother that the patient was given 2 injections of M-M-R II (dose, route, anatomical location and lot # were not reported). No adverse effects were reported. A Product Quality Complaint was not involved. Additional information is not expected since the physician cannot be contacted.
Sore at injection site 3 days Sore armpit 4 days Fever, ranging 99 - 101 - 2 days
Pain at injection site started 6 hours post injection. Fever started 24 hours post injection and lasted 12 hours. Fever retuned 16 hours later and lasted 3-4 hours. Rash was noticed about 80 hours post injection.
Low grade fever; Guttate psoriasis; Diarrhea; This spontaneous case was reported by a consumer and describes the occurrence of GUTTATE PSORIASIS (Guttate psoriasis), DIARRHOEA (Diarrhea) and PYREXIA (Low grade fever) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032M20A) for COVID-19 vaccination.     Concurrent medical conditions included Psoriatic arthritis. Concomitant products included CERTOLIZUMAB PEGOL (CIMZIA) and METHOTREXATE for Psoriasis.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Mar-2021, the patient experienced GUTTATE PSORIASIS (Guttate psoriasis). On an unknown date, the patient experienced DIARRHOEA (Diarrhea) and PYREXIA (Low grade fever). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency. At the time of the report, GUTTATE PSORIASIS (Guttate psoriasis), DIARRHOEA (Diarrhea) and PYREXIA (Low grade fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient received 1 dose of the Moderna Covid-19 vaccine by injection to their arm on 9-MAR-2021 and 8 days after receiving the vaccine, they broke out with a rash over their entire body, but not on their head and neck. The patient also had a low grade fever at this time and had a history of psoriatic arthritis and was told that this rash was a guttate psoriasis. The rash was like chicken pox all over their body. Reportedly, the patient spoke to their dermatologist and a few other doctors, then took Benadryl, and used steroid creams and foams for their rash. The patient was taking Cimzia for their psoriasis at that time and was now taking methotrexate as well. More recently, they had been experiencing 3 weeks of diarrhea.  Treatment medications also reported included steroid creams and foams for the rash.
sore arm; This is a spontaneous report from a contactable consumer. A 66-years-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/lot number: GN620, Expiration date: unknown) via an unspecified route of administration on 13Feb2021 16:30 at right arm at single dose for COVID-19 Immunization. Historical vaccine included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, batch no: EL9261) on 22Jan2021 15:00, anatomical location was right arm and experienced sore arm on 23Jan2021 08:00. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Patient's Concomitant medications included Simvastatin 20mg once a day (for High cholesterol), Zyrtec 1tablet a day (For allergies), Centrum vitamin, Vitamin D (1tablet/day) and Caltrate (2tablet/day). On 14Feb2021 08:00, patient experienced sore arm. Reporter assessed the event as non-serious. The outcome of the event was unknown.  Additional information has been requested.
Nausea and vomiting brought patient to the ED.  X-ray and ultrasound showed evidence of intussusception.  Patient transferred to another hospital for treatment.
This case was reported by a physician via call center representative and described the occurrence of lymphadenopathy in a 26-year-old female patient who received FLUARIX (batch number 3JE9F, expiry date unknown). In September 2014, the patient received FLUARIX. On an unknown date, less than a week after receiving FLUARIX, the patient experienced lymphadenopathy, injection site reaction and fever. On an unknown date, the outcome of the lymphadenopathy, injection site reaction and fever were recovered/resolved. It was unknown if the reporter considered the lymphadenopathy, injection site reaction and fever to be related to FLUARIX. Additional details provided were as follows: According to the reporter the patient was nurse and last year in September 2014 at the hospital, she received a dose of FLUARIX. Nex day (less than a week) after vaccination, the patient noticed swelling of the axillary lymph nodes and cervical lymph nodes on the left side where the vaccine was administered. An unspecified time after vaccination, additionally the patient experienced a large local reaction at the injection site and a low-grade fever of 101 degree F. On an unknown date, the patient was seen by her physician and the patient did not receive any treatment for it. The symptoms resolved after couple of days.
4/17/23   I started feeling like I had a scratchy throat and very tired. Two days progressed and I began feeling worse. By that week-end, I needed to sleep sitting up because I could not breathe. I went to an after-hours clinic and was prescribed Benzonatate for 15 days. I got worse, to the point my ribs felt like they were broken I was coughing so much. I called my PCP and she prescribed Doxycycline. After a few days, I began to feel better. I am still tired, but feel much better and am doing the things I normally do.
At 11:00, on 1/19/01, temperature of 106F. Child admitted to hospital by PMD. The child had a rash and fever. In 24 hours, temperature went down and was discharged at 15:00 on 1/20/01. At 23:00 on 1/20/01, temperature was 104F. Admitted to the hospital again with rash and temperature which fluctuated for 2 weeks. Child was discharged on 1/30/01.
Flu like symptoms- runny nose, headache, fatigue, and small fever; Flu like symptoms- runny nose, headache, fatigue, and small fever; Flu like symptoms- runny nose, headache, fatigue, and small fever; Flu like symptoms- runny nose, headache, fatigue, and small fever; Flu like symptoms- runny nose, headache, fatigue, and small fever; This is a spontaneous report from a contactable consumer (patient's mother). A 12-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: Not provided) via an unspecified route of administration on 26May2021 as single dose for COVID-19 immunization. Patient medical history and concomitant medications were not provided. On 14Jun2021, the patient was having flu like symptoms - runny nose, headache, fatigue, and small fever. He has been scheduled for dose 2 tomorrow (on 16Jun2021). The reported asked what they should do about that and how long can he wait between injections like the max number of days. She states she received the Fact Sheet for Recipients and Caregivers and they didn't mention how long you can go between doses. It only says three weeks. Outcome of the events was unknown.  Follow up attempts are needed; information about lot/batch number has been requested.
A PUNCTURED VIAL LEFT IN REFRIGERATOR FOR MORE THAN 6 HOURS; MEDICATION ERROR; This spontaneous report received from a pharmacist concerned multiple patients. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 211D21A expiry: 04-NOV-2022) dose was not reported, administered on 16-NOV-2021 for prophylactic vaccination. No concomitant medications were reported.  On 16-NOV-2021, the patient experienced medication error. On an unspecified date, the patient experienced a punctured vial left in refrigerator for more than 6 hours. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the medication error and a punctured vial left in refrigerator for more than 6 hours was not reported. This report was non-serious.
Bad Headache, back pain, joint pain, sensitive to touch and light, pain at injection sight, mild nausea for about 24 hours. Headache and fatigue the 2nd 24 hours
Yesterday (2/10, 15 days after my second Moderna injection) I developed morbilliform rash on my torso and all extremeties. No decrease in symptoms after adminsitration of benadryl and zyrtec. I went to the dermatologist today who diagnosed it as a morbilliform rash reaction to the Moderna vaccine.
headache; This is a spontaneous report from a non-contactable consumer (patient). A 22-year-old male patient received BNT162B2 (Pfizer-BioNTech COVID-19 vaccine, lot number: EL3247), via an unspecified route of administration on 23Feb2021 as a single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported.  The patient did not have COVID prior to the vaccination. It was reported that the patient got a headache on 24Feb2021, the day after receiving the vaccine. The patient was tested for COVID via a nasal swab on 25Feb2021 with a result of negative. The outcome of the event was unknown.   No follow-up attempts are possible; No further information is expected.
Patient was to receive the adult dose of the Pfizer Covid Vaccine. She instead received an undiluted 0.3ml dose of the kids Pfizer Covid Vaccine. This was originally thought to have been a diluted dose so it was looked into by the clinical coordinator to be corrected with an immediate readministration of a full adult dose. It was then discovered that the original dose given was an undiluted kids version. The patient has been made aware of the situation and it will be followed up on over the next few days. Possible to expect more flu like symptoms due to the increase in net dose from what was expected/recommended to get. Left arm was given the kids  Right arm was given the adult
Patient is hospitalized with pneumonia and COVID-19. Patient is having a difficult time breathing, mild cough, and pains. Patient was seen at facility on 09/13/2021 and was there until a bed was available at Hospital where he is currently. Patient is fully vaccinated.
Recipient of vaccine is a family member (father) of employee of Hospital.  Recipient was vaccinated with Dose 2 Pfizer Covid vaccine on 3/19/2021 and observed on-site for 15 minutes after vaccination with no apparent concerns.  On 3/23/2021, his daughter (our employee) notified clinic that on  3/22/2021, recipient had died.  4/7/2021 his daughter (our employee) states the medical examiner indicated his autopsy showed evidence of cardiac arrest.
When patient came in for her second dose of Moderna vaccine at 28 weeks, she reported a reaction that occurred about 10 to 12 day after the first dose at the site where her injection was given. She brought pictures on her cell phone of a large of erythema and raised hard bumps that covered most of her upper outer arm. The area was approximately 9cm top to bottom x 7cm wide. It first felt itchy, then broke out in this dense red rash. She was seen by her primary physician who told her it looked like an allergic medicine reaction and he advise against taking a second dose. She came in to see what we advised her to do. We advised her to follow her physician's recommendations and withheld the second dose of Moderna.
Patient is 8 weeks pregnant and experiencing significant nausea and vomiting--patient stated that she had vomited on the way to the store.  After receiving the vaccine, the patient immediately said she thought she was going to pass out.  She experienced tingling in arms and legs particularly in forearm of left arm.  She also complained that she felt dizzy, warm and lightheaded.  Patient was assisted in laying down, given an icepack (applied to back of neck) and water to drink.  Patient's temperature was taken and determined to be normal.  After 30 minutes of observation, patient said she felt better and only had a mild headache.  A friend drove her home.   Patient also mentioned that her anxiety levels have been very high during this pregnancy, but she is not currently taking anything for anxiety.
Soreness of right arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Soreness of right arm) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 033C2A and 027B21A) for COVID-19 vaccination.     No medical history was reported.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-May-2021, the patient experienced PAIN IN EXTREMITY (Soreness of right arm). The patient was treated with DIPHENHYDRAMINE CITRATE, IBUPROFEN (MOTRIN PM) at a dose of UNK dosage form and PREDNISONE at a dose of UNK dosage form. On 08-May-2021, PAIN IN EXTREMITY (Soreness of right arm) had resolved.            No concomitant medications were reported.  No laboratory details were  provided.  No treatment medications were reported.  Action taken with mRNA-1273 in response to the events was not applicable.   Patient received it in her right arm and patient experienced sore arm but resolved after 2-3 days.
scratchy throat; This is a Spontaneous report from Pfizer program. A contactable female consumer (patient) of unspecified age reported that she received bnt162b2 (BNT162B2), dose 1 via an unspecified route of administration on 13Mar2021 (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation.  The medical history and concomitant medications were not reported.  The patient experienced scratchy throat in 2021 with outcome of unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
This spontaneous report received from a parent via a company representative concerned a male of unspecified age. The patient's height, and weight were not reported. The patient's past medical history included: covid-19, and other pre-existing medical conditions included: Patient had family history of Multiple sclerosis and had a higher risk of Guillain Barre. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the patient experienced sick from vaccine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of sick from vaccine was not reported. This report was non-serious. This case, from the same reporter is linked to 20211032083.
After injection #1 on 03/08/2021 a bit of soreness felt in my right arm prior became much worse and my shoulder felt almost like it was out of joint.  After the second dose of the vaccine my right arm became so sore that i was unable to lift it, had intense pain while sleeping, and the pain also was in my left shoulder though not as severe. In addition to this my neck lymph node on the right side continues to be swollen.  Dr gave me anti-inflamatory medicine and some exercises and antibiotic for the lymph node.  I am still suffering from both the swollen lymph node and shoulder pain and have just seen an orthopedist who is starting physical therapy and I get an MRI on Friday 06/11/2021.